EUVIMEDEUVIMED entdecken
Crossref

Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study

Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · e9-e10

DOI: 10.1016/j.cgh.2026.07.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clinical Gastroenterology and Hepatology, 24(10), e9-e10. https://doi.org/10.1016/j.cgh.2026.07.025

Vancouver

Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clinical Gastroenterology and Hepatology. 2026;24(10):e9-e10. doi:10.1016/j.cgh.2026.07.025

BibTeX
@article{euvimed2026,
  title = {Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {10},
  pages = {e9--e10},
  doi = {10.1016/j.cgh.2026.07.025}
}
Kostenlos starten →